King Pharmaceuticals, Inc. (NYSE:KG) today announced the appointment of
John J. Howarth to Vice President, Investor Relations. Mr. Howarth joins
King with over 25 years of experience in the healthcare industry,
including executive positions at specialty pharmaceutical companies, as
well as large global pharmaceutical companies.
“We are extremely pleased to add Jack to our team,” stated Joseph
Squicciarino, King’s Chief Financial Officer. “We are confident that
Jack’s expertise in investor relations and extensive knowledge of the
specialty pharmaceutical industry will complement our senior management
team as we focus on executing our long-term growth strategy.”
Most recently, Mr. Howarth was Vice President, Investor Relations at
Alpharma Inc., which King acquired in December 2008. Previously, he
served in similar roles at MedPointe Pharmaceuticals and Kos
Pharmaceuticals. Mr. Howarth received his BS degree in accounting from
Boston College and an MBA in finance from Seton Hall University.
About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and
acquisitions, of novel branded prescription pharmaceutical products and
technologies that complement the Company’s focus in specialty-driven
markets, particularly neuroscience and hospital. King is also a leader
in the development, registration, manufacture and marketing of
pharmaceutical products for food producing animals.
King Pharmaceuticals, Inc.
Jack Howarth, 908-429-8350
Vice
President, Investor Relations
